A condition affecting millions of women worldwide has a new name. After a global consensus process that included over 14,000 survey responses and input from 56 organizations, polycystic ovarian syndrome (PCOS) is now called PMOS1, which stands for polyendocrine metabolic ovarian syndrome. The name change reflects a shift in how the medical community understands the condition, which affects an estimated 170 million women globally.
The old name was always somewhat inaccurate. The condition does not actually involve pathological ovarian cysts, despite what the name suggested. What appear as “cysts” on some ultrasounds are actually immature follicles, which are a symptom of hormonal dysfunction rather than the cause. This naming confusion had real consequences. By centering the ovaries, the old terminology obscured the condition’s true nature as a multi-system syndrome involving hormones, metabolism, and ovarian function.
Research confirms the scope of the problem. A 2025 study found that while population-based data show PCOS prevalence of 4 to 19.6 percent, health system records capture only 0.2 to 5.2 percent. This diagnostic gap is not evenly distributed. Studies show that Black and African American patients are 69 percent more likely to have a missed diagnosis compared to non-Hispanic White patients.
The new name can be broken down into three components. Polyendocrine means the condition involves multiple hormone systems, including reproductive hormones, androgens like testosterone, insulin, and neuroendocrine hormones that affect everything from mood to metabolism. Metabolic means insulin resistance is a core feature for many women with this condition, carrying significant downstream risks. Ovarian means ovarian dysfunction remains part of the picture, capturing irregular cycles, anovulation, and fertility challenges.
The metabolic component deserves particular attention. A 2025 study describes a bidirectional relationship between insulin resistance and PMOS symptoms like hyperandrogenism and ovulatory dysfunction. PMOS itself also increases risk of type 2 diabetes. This is evidence of how PMOS has reproductive, metabolic, and psychological impacts across a person’s lifespan.
When clinicians hear PCOS, they think “polycystic ovaries” and look for ovarian cysts and menstrual irregularities when diagnosing patients. With the new name “polyendocrine metabolic ovarian syndrome,” the diagnostic lens widens considerably. This matters because many women with PMOS do not fit the narrow “classic” presentation. Some have regular periods. Others present with irregular menstrual cycles but do not have visible follicles on an ultrasound. Symptoms like insulin resistance, elevated androgens, acne, hair changes, or metabolic markers can point to the same underlying dysfunction.
The hope is that reframing the condition as metabolic and endocrine, instead of simply gynecological, will prompt earlier and more comprehensive screening. A woman presenting with unexplained weight gain, fatigue, and skin changes might now be evaluated for PMOS rather than having her symptoms dismissed or siloed into separate specialty visits.
For those who have been diagnosed with PCOS, now PMOS, the name change validates what many have long known. This condition is not just about the ovaries. It is a whole-body condition that deserves whole-body care, including metabolic screening, cardiovascular risk assessment, and attention to mental health. For those who have suspected something was off but have not gotten answers, the evolving understanding of PMOS may work in their favor. Asking a healthcare provider about comprehensive hormone and metabolic testing, not just an ultrasound, may help. Understanding the differences between PMOS and other conditions like endometriosis can also help patients advocate for themselves.
The renaming of PCOS to PMOS reflects decades of research showing this condition extends far beyond the ovaries. For millions of women affected worldwide, this validates the ripple effects of the diagnosis that extend far beyond reproductive and gynecological health. The new terminology may lead to earlier diagnosis, more comprehensive care, and better recognition of the metabolic and hormonal factors that shape women’s health.
